It was announced today that Pfizer will be acquiring Vicuron Pharmaceuticals, a company that focuses on novel anti-infectives for both hospital-based and community-acquired infections. "By acquiring Vicuron, we can help bring two very important new medicines to patients around the world," said Hank McKinnell, the chairman and CEO of Pfizer. The two medicines that he is talking about are anidulafungin for fungal infections and dalbavancin for Gram-positive infections. They are both currently under New Drug Application (NDA) at the FDA.
latest ebusiness news. 
No comments yet. Be the first to comment!